Remote Trial - Tobacco Product Standard (VLNC)

Not Applicable

Terminated

• Conditions: Tobacco Use
• Interventions: Other: Tobacco and non-tobacco e-cigarettes; Other: Tobacco only e-cigarettes

• Registration Number: NCT06442384
• Lead Sponsor: Masonic Cancer Center, University of Minnesota

Brief Summary

The goal of this pilot project is to explore the feasibility of a real-world marketplace study design examining the effects of a reduced nicotine product standard for cigarettes on smoking in the context of a flavor restriction vs. no restriction on e-cigarettes in smokers switched to very low nicotine content cigarettes.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-05-29
• Study First Submitted QC: 2024-05-29
• Study First Posted: 2024-06-04
• Study Start: 2024-09-11
• Status Verified: 2025-04
• Primary Completion: 2025-04-07
• Study Completion: 2025-04-07
• Last Update Submitted: 2025-04-08
• Last Update Posted: 2025-04-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Self-report of daily smoking of at least 5 to 25 cigarettes for >3 months by self-report.
• Carbon monoxide indicative of regular smoking (CO > 6ppm) prior to randomization.
• Has regular access to a smartphone, tablet or computer with functioning camera and internet access for telehealth visits and surveys and to take photos of receipts.
• Lives in an area where VLN® cigarettes are being marketed (these locations may vary during the course of the study).

Exclusion Criteria

• Unstable health conditions (any significant serious, unstable medical condition including, but not limited to, cardiovascular disease, liver or kidney disease, COPD, bronchitis, within the past 3 months, seizure disorder and cancer (cancer-free <5 years except some skin cancers can be within 5 years), or a COVID-19 positive test or COVID-19 symptoms in the last 14 days or as determined by the licensed medical professional at each site).
• Unstable mental health (to be determined by medical history, Patient Health Questionnaire-2 (Prime-MD) and GAD-2 after review by the licensed medical professional).
• Excessive drinking or problems with drinking or drugs-including marijuana (assessed by PI or licensed medical professional).
• Currently pregnant, breastfeeding or intending to become pregnant for the duration of the study or unwilling to agree to use adequate protection to avoid pregnancy.
• Taking exclusionary medications, unstable dosing of medications, or unstable control of symptoms for ongoing medical conditions (medications or conditions that would impact patient safety to be determined by the licensed medical professional).
• Recent experience with VLNC cigarettes (purchasing of the VLNC cigarettes in the past year)
• Household member enrolled in the study concurrently.
• Participated in prior research study during the past three months that would impact baseline smoking or response to study products.
• Inability to independently read and comprehend the consent form and follow other written study instructions, materials or measures or behavior indicating inability to fully participate in study procedures. Participants are required to complete the protocol at home independently and must show ability to comply with directions.
• Unstable living environment that would compromise the ability to sequester study products or complete study procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VLNC cigarettes plus access to tobacco and non-tobacco flavored e-cigarettes	Tobacco and non-tobacco e-cigarettes	Smokers who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Participants will then be randomly assigned to a 4-week intervention
VLNC cigarettes plus access to only tobacco flavored e-cigarettes	Tobacco only e-cigarettes	Smokers who meet eligibility criteria will enter 2 weeks of monitoring of usual brand smoking. Participants will then be randomly assigned to a 4-week intervention

Primary Outcome Measures

Name	Time	Method
Percent of participants that drop-out by 4 week visit	4 weeks	Percent of participants that drop-out by 4 week visit

Secondary Outcome Measures

Name	Time	Method
Change in mean cigarettes per day (CPD)	Baseline to 4 weeks	Change in mean cigarettes per day (CPD) based on 7 day ITR data before visit 00 and week 4 visits
Number of participants experiencing smoke free days	4 weeks

Trial Locations

Locations (1)

Masonic Cancer Center; 🇺🇸 Minneapolis, Minnesota, United States